NCT04866017
Who may be able to join
Who might be able to join this trial:
- You must be 18 years old or older (or meet the legal age of consent in your country) at the time of signing the consent form.
- You must have been diagnosed with a specific type of lung cancer (non-small cell lung cancer, Stage III) that cannot be removed by surgery, confirmed through a tissue or cell sample.
- You must have already completed at least 2 rounds of a platinum-based chemotherapy given at the same time as radiation therapy.
- Your lung cancer must not have gotten worse during or after that combined chemotherapy and radiation treatment.
- You must be generally well enough to carry out daily activities, with only mild limitations at most (confirm with trial site).
- Your liver, kidneys, and other organs must be working well enough as shown by blood tests (confirm with trial site).
- You must be willing to provide a stored tumor tissue sample, or have a new tissue sample taken before treatment if no stored sample is available, so researchers can test it.
Who may not be able to join:
- You have previously received certain immunotherapy drugs that target specific immune system pathways, such as anti-PD-1 or anti-PD-L1 treatments (confirm with trial site).
- Your lung cancer has certain specific gene mutations or changes, including EGFR, ALK, ROS1, or RET (confirm with trial site).
- You received any other cancer treatments beyond the combined chemotherapy and radiation therapy described above.
- You are still experiencing side effects of Grade 3 or higher from your previous chemotherapy and radiation treatment (confirm with trial site).
- You have an active autoimmune disease, or a history of one that could come back.
- You have needed to take moderate-to-high doses of steroid medications or other immune-suppressing drugs within the last 14 days before starting the trial.
- You have had an active infection requiring antibiotic, antifungal, or antiviral treatment within the last 14 days — though ongoing antiviral treatment for chronic hepatitis B or C is allowed.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Trial details
Where this trial is recruiting
7 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Progression-Free Survival (PFS) as Assessed by the Independent Review Committee (IRC)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.